ATE474569T1 - Verwendung von sphingosin-1-phosphat (s1p) rezeptor-agonisten zur behandlung von degenerativen gehirnerkrankungen - Google Patents

Verwendung von sphingosin-1-phosphat (s1p) rezeptor-agonisten zur behandlung von degenerativen gehirnerkrankungen

Info

Publication number
ATE474569T1
ATE474569T1 AT04804037T AT04804037T ATE474569T1 AT E474569 T1 ATE474569 T1 AT E474569T1 AT 04804037 T AT04804037 T AT 04804037T AT 04804037 T AT04804037 T AT 04804037T AT E474569 T1 ATE474569 T1 AT E474569T1
Authority
AT
Austria
Prior art keywords
sphingosine
phosphate
treatment
receptor agonists
brain diseases
Prior art date
Application number
AT04804037T
Other languages
English (en)
Inventor
Volker Brinkmann
Nicole Kaneider
Christian Wiedermann
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE474569T1 publication Critical patent/ATE474569T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04804037T 2003-12-19 2004-12-17 Verwendung von sphingosin-1-phosphat (s1p) rezeptor-agonisten zur behandlung von degenerativen gehirnerkrankungen ATE474569T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0329498.0A GB0329498D0 (en) 2003-12-19 2003-12-19 Organic compounds
PCT/EP2004/014436 WO2005058295A2 (en) 2003-12-19 2004-12-17 Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases

Publications (1)

Publication Number Publication Date
ATE474569T1 true ATE474569T1 (de) 2010-08-15

Family

ID=30776138

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04804037T ATE474569T1 (de) 2003-12-19 2004-12-17 Verwendung von sphingosin-1-phosphat (s1p) rezeptor-agonisten zur behandlung von degenerativen gehirnerkrankungen

Country Status (17)

Country Link
US (4) US20080139662A1 (de)
EP (2) EP2213285B1 (de)
JP (2) JP2007514698A (de)
KR (2) KR101342244B1 (de)
CN (2) CN101791406B (de)
AT (1) ATE474569T1 (de)
AU (1) AU2004298760B2 (de)
BR (1) BRPI0417203A (de)
CA (2) CA2545503C (de)
DE (1) DE602004028286D1 (de)
ES (2) ES2444717T3 (de)
GB (1) GB0329498D0 (de)
MX (1) MXPA06006924A (de)
PL (1) PL1713459T3 (de)
PT (1) PT1713459E (de)
RU (1) RU2379030C2 (de)
WO (1) WO2005058295A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3103448T (pt) * 2006-09-26 2019-07-12 Novartis Ag Composições farmacêuticas que compreendem um modulador de s1p
EP1905434A1 (de) * 2006-09-26 2008-04-02 Novartis AG Organische S1P Rezeptor Agonist Verbindungen und ihre therapeutische Verwendung
KR20190004843A (ko) 2008-07-23 2019-01-14 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
JP5726737B2 (ja) 2008-08-27 2015-06-03 アリーナ ファーマシューティカルズ， インコーポレイテッド 自己免疫障害および免疫性障害の治療において有用なｓ１ｐ１受容体のアゴニストとしての置換三環式酸誘導体
EP2177521A1 (de) 2008-10-14 2010-04-21 Almirall, S.A. Neue 2-Amidothiadiazol-Derivate
EP2202232A1 (de) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4 Oxadiazolderivate und ihr Einsatz als Arzneimittel
EP2210890A1 (de) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazol Derivate als S1P1 Rezeptor Agonisten
US20120128666A1 (en) * 2009-06-24 2012-05-24 Lpath, Inc. Methods of increasing neuronal differentiation using antibodies to lysophosphatidic acid
UY32858A (es) 2009-08-31 2011-03-31 Abbott Healthcare Products Bv Derivados de (tio)morfolina como moduladores de sip
EP2305660A1 (de) 2009-09-25 2011-04-06 Almirall, S.A. Neue Thiadiazolderivate
EP2343287A1 (de) 2009-12-10 2011-07-13 Almirall, S.A. Neue 2-Aminothiadiazol-Derivate
CN108558740B (zh) 2010-01-27 2021-10-19 艾尼纳制药公司 S1p1受体调节剂及其盐的制备方法
WO2011109279A2 (en) 2010-03-01 2011-09-09 Centocor Ortho Biotech Inc. Methods for purifying cells derived from pluripotent stem cells
CA2789480A1 (en) 2010-03-03 2011-09-09 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
EP2366702A1 (de) 2010-03-18 2011-09-21 Almirall, S.A. Neue Oxadiazolderivate
EP2390252A1 (de) 2010-05-19 2011-11-30 Almirall, S.A. Neue Pyrazolderivate
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
TW201206893A (en) 2010-07-09 2012-02-16 Abbott Healthcare Products Bv Bisaryl (thio) morpholine derivatives as S1P modulators
TWI522361B (zh) 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
KR102203056B1 (ko) 2011-12-22 2021-01-14 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 단일 인슐린 호르몬 양성 세포로의 분화
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
RU2768963C2 (ru) 2012-12-31 2022-03-25 Янссен Байотек, Инк. Культивация эмбриональных стволовых клеток человека в воздушно-жидкостной зоне взаимодействия с целью их дифференцировки в панкреатические эндокринные клетки
WO2014106141A1 (en) 2012-12-31 2014-07-03 Janssen Biotech, Inc. Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
EP2878339A1 (de) * 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3-Antagonisten
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
HUE060476T2 (hu) 2015-06-22 2023-03-28 Arena Pharm Inc (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
CN110545848A (zh) 2017-02-16 2019-12-06 艾尼纳制药公司 用于治疗具有肠外表现的炎症性肠病的化合物和方法
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US12156866B2 (en) 2018-06-06 2024-12-03 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
EP3847158A1 (de) 2018-09-06 2021-07-14 Arena Pharmaceuticals, Inc. Verbindungen zur verwendung bei der behandlung von autoimmun- und entzündlichen erkrankungen
JP7573286B2 (ja) * 2019-08-07 2025-01-21 国立大学法人東京科学大学 軽度認知障害の予防又は治療剤
JP2022553802A (ja) 2019-10-31 2022-12-26 エスケープ・バイオ・インコーポレイテッド Ｓ１ｐ受容体モジュレーターの固体形態

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3154742B2 (ja) * 1991-04-30 2001-04-09 日本石油化学株式会社 哺乳類の動脈硬化症治療剤
WO1994008943A1 (fr) 1992-10-21 1994-04-28 Yoshitomi Pharmaceutical Industries, Ltd. Compose 2-amino-1,3-propanediol et immunosuppresseur
ATE211726T1 (de) 1994-08-22 2002-01-15 Welfide Corp Benzolderivate und deren medizinische verwendung
PT813411E (pt) * 1995-02-15 2002-07-31 Takeda Chemical Industries Ltd Utilizacao de derivados de vinpocetina para inibicao da producao ou da secrecao de proteina amiloide beta
DE19513630A1 (de) * 1995-04-05 1996-10-10 Schering Ag Neue Verwendung von AMPA-Agonisten
HU224814B1 (en) * 1995-12-28 2006-02-28 Mitsubishi Pharma Corp Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases
AU3641597A (en) * 1996-06-21 1998-01-07 Advanced Research And Technology Institute, Inc. Methods and compositions comprising r-ibuprofen
ITMI962356A1 (it) * 1996-11-13 1998-05-13 Uni Degli Studi Di Brescia D I Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di
KR20000075745A (ko) * 1997-02-27 2000-12-26 가마후라 아키오 의약 조성물
USRE39072E1 (en) 1997-04-04 2006-04-18 Mitsubishi Pharma Corporation 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
AU1865499A (en) * 1997-12-30 1999-07-26 Allelix Biopharmaceuticals Inc. Identification of lysolipid receptors involved in inflammatory response
CA2330329C (en) * 1999-02-26 2009-08-25 Marcus Keep Cerebrospinal and vascular pharmaceutical composition and process for preparing the same
US6420369B1 (en) * 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
CA2310990A1 (en) * 2000-04-03 2000-10-09 Michael Pontecorvo A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
EP1300405B1 (de) 2000-07-13 2007-04-18 Sankyo Company, Limited Aminoalkoholderivate
EP1315735A4 (de) * 2000-08-31 2005-04-06 Merck & Co Inc Phosphat-derivate als immunoregulatorische verbindungen
US20030013692A1 (en) * 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
MXPA03008755A (es) * 2001-03-26 2004-02-18 Novartis Ag Derivados de 2-amino-propanol.
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
EP1414423A1 (de) * 2001-07-31 2004-05-06 Lothar Saiger Mittel zur behandlung von depressionen enthaltend ein lokalanästhetikum
DE60235900D1 (de) 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
CA2461212C (en) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
TWI252111B (en) * 2001-12-14 2006-04-01 Solvay Pharm Gmbh Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
ATE441654T1 (de) * 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
WO2003094965A2 (en) * 2002-05-08 2003-11-20 Neuronova Ab Modulation of neural stem cells with s1p or lpa receptor agonists
GB0217152D0 (en) * 2002-07-24 2002-09-04 Novartis Ag Organic compounds
WO2004024673A1 (en) * 2002-09-13 2004-03-25 Novartis Ag Amino-propanol derivatives
US6776328B2 (en) 2002-09-17 2004-08-17 The Boeing Company Radiation assisted friction welding
BR0314760A (pt) * 2002-09-24 2005-07-26 Novartis Ag Compostos orgânicos
ES2383298T3 (es) * 2003-04-30 2012-06-20 Novartis Ag Derivados del amino-propanol como moduladores del receptor esfingosina-1-fosfato
US7838562B2 (en) * 2003-06-24 2010-11-23 University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
WO2005025553A2 (en) * 2003-09-12 2005-03-24 Neuronova Ab Treatment of disorders of nervous systemsystem with fty720
WO2005041899A2 (en) 2003-11-03 2005-05-12 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists

Also Published As

Publication number Publication date
CA2792467A1 (en) 2005-06-30
CA2545503A1 (en) 2005-06-30
HK1097458A1 (en) 2007-06-29
KR101232934B1 (ko) 2013-02-13
CA2545503C (en) 2013-08-20
EP2213285A3 (de) 2010-10-20
RU2379030C2 (ru) 2010-01-20
JP5469122B2 (ja) 2014-04-09
AU2004298760B2 (en) 2009-05-21
US20110124739A1 (en) 2011-05-26
JP2007514698A (ja) 2007-06-07
JP2011148830A (ja) 2011-08-04
KR101342244B1 (ko) 2013-12-16
PL1713459T3 (pl) 2010-12-31
EP2213285A2 (de) 2010-08-04
KR20120099499A (ko) 2012-09-10
MXPA06006924A (es) 2006-08-23
CN1893934A (zh) 2007-01-10
US20130281541A1 (en) 2013-10-24
EP1713459B1 (de) 2010-07-21
EP2213285B1 (de) 2013-11-06
CN101791406B (zh) 2013-08-14
PT1713459E (pt) 2010-09-06
BRPI0417203A (pt) 2007-02-06
KR20060103354A (ko) 2006-09-28
CN101791406A (zh) 2010-08-04
GB0329498D0 (en) 2004-01-28
US8519006B2 (en) 2013-08-27
WO2005058295A3 (en) 2005-11-24
AU2004298760A1 (en) 2005-06-30
WO2005058295A2 (en) 2005-06-30
RU2006125744A (ru) 2008-01-27
US20080139662A1 (en) 2008-06-12
US20140162964A1 (en) 2014-06-12
CN1893934B (zh) 2010-05-26
ES2348569T3 (es) 2010-12-09
EP1713459A2 (de) 2006-10-25
DE602004028286D1 (de) 2010-09-02
ES2444717T3 (es) 2014-02-26

Similar Documents

Publication Publication Date Title
ATE474569T1 (de) Verwendung von sphingosin-1-phosphat (s1p) rezeptor-agonisten zur behandlung von degenerativen gehirnerkrankungen
BRPI0415210A (pt) compostos e composições como inibidores de proteìna cinase
BRPI0409173A (pt) compostos e composições como inibidores de proteìna quinase
BRPI0607307A2 (pt) compostos e composições como inibidores de proteìna cinase
ATE523196T1 (de) Mitotische kinesinhemmer und verfahren zu ihrer verwendung
DE60129242D1 (de) Verwendung von zoledronsäure zur schmerzbehandlung
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
ES2151593T3 (es) Androstanos y pregnanos para modulacion alosterica del receptor de gaba.
WO2006105516A3 (en) Compositions and methods for diagnosing and treating neuropsychiatric disorders
ATE529125T1 (de) Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung
DE60335743D1 (de) Verbindungen und verfahren zur erhöhung der neurogenese
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE466572T1 (de) Verfahren zur hemmung der gefässpermeabilität und apoptose
BRPI0414049A (pt) compostos e composições como inibidores de proteìna cinase
NO20076186L (no) Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav
DE69825286D1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
ATE366045T1 (de) Verwendung von 4-aminopyrimidinen zur antimikrobiellen behandlung von oberflächen
DE602007005353D1 (de) PyrazoloÄ1,5-aÜpyrimidine Derivate zur Verwendung in der Behandlung von Morbus Alzheimer und verwandten Leiden
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
WO2007023310A3 (en) Stimulation of neurogenesis with help of alk inhibitors
AU2002335027A1 (en) Treatment of tnf-alpha-mediated disorders with casein kinase i epsilon inhibitors
PL390683A1 (pl) Zastosowanie pochodnych pirolu do wytwarzania leku
ATE425756T1 (de) Verwendung von carbamazepinderivaten zur behandlung von agitatio in demenspatienten
ATE422500T1 (de) Neue chelidonin-derivate, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von pharmazeutischen wirkstoffen
JO2724B1 (en) 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1713459

Country of ref document: EP